Corporate ActionSep 29, 2026, 08:36 AM
Ensysce Biosciences Amends Preferred Stock Terms
AI Summary
Ensysce Biosciences, Inc. filed a Certificate of Amendment to its Series C Non-Voting Convertible Preferred Stock designation. The amendment removes Section 6.5.3, which previously allowed Series C Preferred Stock holders to redeem their shares for cash under certain conditions, including failure to deliver common stock upon conversion. This amendment was effective upon filing.
Key Highlights
- Ensysce Biosciences amended the Series C Certificate of Designation to remove Section 6.5.3.
- Section 6.5.3 provided for redemption of Series C Preferred Stock at holder's option under specific conditions.
- The amendment was effective upon filing with the Secretary of State of Delaware on September 25, 2026.
Price Impact
More from ENSC